Shots:
BeiGene’s Tevimbra has received the US FDA’s approval as a monotx. to treat unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after previous systemic chemotherapy (CT) excl. PD-(L)1 inhibitor. The US availability is anticipated in H2’24
The approval was supported by the P-III (RATIONALE 302) study assessing the safety & efficacy of Tevimbra vs…
